Entera Bio Ltd. (NASDAQ:ENTX) Q2 2021 Earnings Conference Call August 16, 2021 8:30 AM ET Company Participants Spiros Jamas - CEO Ramesh Ratan - US-based CFO Arthur Santora - CMO Phillip Schwartz – President, R&D Conference Call Participants Kalpit Patel – B. Riley Financial, Inc. Operator Good morning, and welcome to Entera Bio's Conference Call to discuss the Financial and Operating Results for the six months Ended June 30, 2021. At this time, all participants are in a listen-only mode. After the speakers ...

Entera Bio Ltd. (NASDAQ:ENTX) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Jon Lieber – US-based Chief Financial Officer Spiros Jamas – Chief Executive Officer Art Santora – Chief Medical Officer Phillip Schwartz – President-R&D Conference Call Participants Jason McCarthy – Maxim Group Calvin Hori – Hori Capital Operator Good morning, and welcome to Entera Bio's Conference Call to discuss the Financial and Operating Results for the Year Ended December 31, 2020. At this tim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 O ...

Entera Bio Ltd. (NASDAQ:ENTX) Q3 2020 Earnings Conference Call November 19, 2020 8:30 AM ET Company Participants Jon Lieber - U.S. Chief Financial Officer Roger Garceau - Interim CEO Phillip Schwartz - President of R&D Arthur Santora - Chief Medical Officer Conference Call Participants Operator Good morning, and welcome to Entera Bio's Conference Call to discuss the Financial and Operating Results from the Third Quarter of 2020. At this time, all participants lines are in a listen-only mode. After the speak ...

Entera Bio Ltd. (NASDAQ:ENTX) Q2 2020 Results Conference Call August 20, 2020 8:30 AM ET Company Participants Jon Lieber - U.S. CFO, Entera Roger Garceau - Interim CEO Dr. Phillip Schwartz - President of R&D Arthur Santora - Chief Medical Officer Conference Call Participants Brett Hoffman - Maxim Group Operator Good morning and welcome to Entera Bio's Conference Call to discuss the Interim Six Month Results from the EB613 Phase 2 Clinical Trial and the Financial and Operating Results from the Second Quarter ...

Call Start: 08:30 January 1, 0000 8:56 AM ET Entera Bio Ltd. (NASDAQ:ENTX) Q1 2020 Results Earnings Conference Call May 21, 2020, 08:30 AM ET Company Participants Jonathan Lieber - U.S. CFO, Entera Adam Gridley - CEO Phillip Schwartz - President of R&D Arthur Santora - Chief Medical Officer Conference Call Participants Operator Good morning and welcome to Entera BioÂ's Conference Call to discuss the Interim Biomarker Data from the Phase 2 clinical trial of EB613 and the Financial and Operative Results from ...

Entera Bio Ltd. (NASDAQ:ENTX) Q4 2019 Earnings Conference Call March 26, 2020 8:30 AM ET Company Participants Jonathan Lieber - U.S. CFO, Entera Adam Gridley - CEO Phillip Schwartz - President of R&D Arth Santora - Chief Medical Officer Conference Call Participants Naureen Quibria - Maxim Group Eric Rubenstein - Intuitive Venture Partners Operator Good morning and welcome to Entera Bio’s 2019 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |--------------------------------------------------------------|---------------- ...

Financial Data and Key Metrics Changes - Revenues for the nine months ended September 30, 2019, were $134,000 from services provided to Amgen under their licensing agreement [55] - Total operating expenses for the same period were $7.9 million, with research and development expenses at $5.2 million and general and administrative expenses at $2.8 million [56] - Total cash as of September 30, 2019, was $5.9 million, expected to fund operations into the first quarter of 2020 [56] Business Line Data and Key Metrics Changes - The company is focusing on its lead program, EB613, for osteoporosis, which is seen as a highly de-risked Phase 2 candidate with a well-defined Phase 3 clinical trial design [12][15] - The secondary program, EB612, for hypoparathyroidism, reported positive results from a Phase 2 study, confirming effective delivery into the bloodstream [29] Market Data and Key Metrics Changes - The osteoporosis market is expected to grow significantly, particularly in regions like China due to aging populations and increased affordability of drugs [18][50] - The company is exploring opportunities in both China and Japan, with strong interest in collaboration regarding its lead programs [51] Company Strategy and Development Direction - The company aims to transform the treatment paradigm for osteoporosis by introducing a less expensive, once-daily oral tablet, targeting the 90% of osteoporotic patients who are not currently treated [16][17] - There is a commitment to executing lead programs, developing new candidates in large markets, and engaging in targeted business development efforts [15][20] Management's Comments on Operating Environment and Future Outlook - Management believes 2020 will be a critical year with significant data readouts expected from the Phase 2 osteoporosis program [58] - The recent recall of a competitor's product has heightened awareness for better therapies in the market, which may benefit the company's programs [68] Other Important Information - The company has established its U.S. headquarters in Boston and is expanding its team to support business development and regulatory efforts [20] - The collaboration with Amgen for an anti-inflammatory agent has progressed well, with positive results from studies conducted [33] Q&A Session Summary Question: Impact of Takeda's Natpara recall on EB612 program - Management noted that the recall has created heightened awareness regarding the need for better therapies, which could benefit both their programs [68] Question: Size of Phase 3 trial for EB612 - The anticipated Phase 3 program for EB612 is expected to include around 100 to 150 patients, typical for orphan indications [72]

Entera Bio Ltd. (NASDAQ:ENTX) Q2 2019 Earnings Conference Call August 20, 2019 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Adam Gridley - CEO Phillip Schwartz - President of Research and Development Dana Yaacov-Garbeli - Interim CFO Conference Call Participants Naureen Quibria - Maxim Group Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Entera Bio Second Quarter 2019 Conference Call. All lines have b ...